It is generally thought that Ras proteins must bind to the plasma membrane to function efficiently in signal transduction cascades controlling growth and differentiation (1) . The Ras protein of Harvey sarcoma virus is bound to the cytoplasmic side of the plasma membrane (2) . Pulse-chase experiments show that the protein is first produced as a cytosolic precursor and then becomes post-translationally converted into a membrane-bound form; this step requires the C terminus of the protein (3) . Further studies show that viral Ras can be labeled in cells incubated with [ 3 H]palmitic acid (4) . C-terminal deletions or mutation of cysteine 186 near the C terminus of Harvey sarcoma virus Ras to serine block incorporation of the palmitoyl group into Ras, and membrane binding and transformation are prevented as well (5) .
Although it was initially thought that cysteine 186 is the site of palmitoylation (6) , more recent studies have convincingly shown that Ras proteins undergo a more complicated array of modifications. It is now generally accepted that most, if not all, Ras proteins contain a C-terminal S-farnesyl-cysteine ␣-methyl ester (7-9), a modification that was first found in fungal mating peptides and in the human nuclear membrane-bound protein lamin B (10 -13) . Ras proteins are first farnesylated on cysteine 186 by a soluble protein farnesyltransferase (14) . This cysteine is part of a C-terminal motif Cys-Ali-Ali-Xaa (Ali is usually but not necessarily an aliphatic amino acid, and Xaa is a variety of different amino acids). After farnesylation, the last three amino acids are removed by proteolysis (15) (16) (17) , and the newly exposed ␣-carboxyl group of the farnesylated cysteine is methylated (17, 18) .
Mammalian N-and H-Ras proteins contain additional cysteines near their C termini (181 for N-Ras and 181 and 184 for H-Ras), and these serve as palmitoylation sites (8, 19) . The functional consequences of these palmitoylations are beginning to be understood. Palmitoylation increases the affinity of farnesylated Ras proteins for membranes (20, 21) . K-Ras4B lacks these upstream cysteines and is prenylated, proteolyzed, and methylated but not palmitoylated. Instead, K-Ras4B has a cluster of 8 lysine residues near its C terminus that are thought to function in membrane anchoring by forming electrostatic contacts with negatively charged phospholipids (20 -22) . Studies with cell lines overexpressing oncogenic H-Ras indicate that mutation of the palmitoylation sites causes a loss in membrane binding, although cell transformation still occurs (8) . However, microinjection experiments in Xenopus oocytes reveal that palmitoylation of H-Ras dramatically enhances its affinity for membranes, and its ability to activate mitogen-activated protein kinase and initiate meiotic maturation (23) . Similar to mammalian cells, lipidation of yeast Ras is also required for tight plasma membrane binding and efficient Ras function, although mutant yeast Ras that cannot be lipidated can function if overexpressed in cells (24, 25) . Interestingly, although yeast containing a single copy of a mutant form of Ras2 that produces a protein that is farnesylated but cannot be palmitoylated show no marked growth phenotype, they fail to induce a transient increase in intracellular cAMP in response to glucose (26) . This suggests that non-palmitoylated Ras2 is unable to activate adenylate cyclase, which is thought to be the main downstream effector in the glucose signaling pathway in yeast.
Of all the C-terminal modifications of Ras, those that are likely to be reversible from a chemical standpoint are palmi-toylation and methylation. Indeed, pulse-chase experiments demonstrate that palmitoylation of N-Ras is a reversible process (27) , which suggests that this post-translational modification may have a regulatory role. An enzyme that removes the palmitoyl group from H-Ras has been purified to homogeneity (28) . The fact that this enzyme contains asparagine-linked carbohydrate and an N-terminal leader sequence, as deduced from the cDNA clone (29) , suggests that the thioesterase is secreted, and thus it is probably not the enzyme that removes the palmitoyl group from Ras in vivo. The palmitoylation of N-Ras and H-Ras have been detected in cell-free homogenates (19, 30) , but the enzyme has never been purified. Despite the fact that many eukaryotic proteins are palmitoylated (31, 32) , no protein palmitoyltransferase has been purified to date. In this paper, we describe the purification from rat liver membranes of an enzyme that palmitoylates both H-Ras protein and a peptide with the structure of the C terminus of N-Ras. Characteristics of this enzyme are presented which suggest that it may be responsible for Ras palmitoylation in vivo.
EXPERIMENTAL PROCEDURES
Materials-The farnesylated and methylated peptide that has the sequence of the C-terminal 16 residues of human N-Ras, LNSSD-DGTQGCMGLP-(S-farnesyl-cysteine-␣-carboxyl methyl ester) (N-Ras-16-mer) 1 was prepared as described (33) . The analogous peptides in which the farnesylated cysteine methyl ester is replaced by cysteine methyl ester or in which the upstream cysteine is changed to serine or S-t-butylthio-cysteine have been described (33) . Storage of N-Ras-16-mer in N,N-dimethylformamide for prolonged periods sometimes results in oxidation of the thioether to the sulfone; this is prevented by storing the peptide under Ar at Ϫ80°C. All peptides were purified to homogeneity by HPLC and their structures were confirmed by mass spectrometry (33) .
Farnesyl pyrophosphate, [1-14 C]palmitic acid (50 mCi/mmol), [9, H]myristoyl-CoA (40 Ci/mmol), and [9, H]palmitic acid (60 Ci/ mmol) are from American Radiolabeled Chemicals. Non-radiolabeled palmitoyl-CoA and myristoyl-CoA are from Sigma. All protein chromatography media are from Pharmacia except Ni 2ϩ -NTA-agarose which is from Qiagen. All aqueous solutions were prepared with purified water (Milli-Q, Millipore). All reagents for insect cell culture are from Life Technologies, Inc.
[ 3 H]Palmitoyl-CoA was prepared from [9, H(N)]palmitic acid (60 Ci/mmol) diluted to 5 Ci/mmol with non-radioactive palmitic acid. The fatty acid (2 mol) was converted to palmitoyl chloride as described (34) . A solution of 0.8 mg of CoA trilithium salt (Sigma) in 0.34 ml of 150 mM NaHCO 3 , pH 11.5, containing 0.15 ml of freshly distilled tetrahydrofuran was added (the published procedure indicates pH 8.6, which was found to give low yields in our hands). The mixture was vigorously stirred at 37°C for 1 h. Radiolabeled palmitoyl-CoA was purified by precipitation with perchloric acid followed by washing with acetone and ether (34) . After removing the ether with a stream of Ar, the product was dissolved in 10 mM sodium phosphate, pH 6.1, and stored at Ϫ80°C. Radiochemical purity was checked by TLC as described (34) and found to be Ͼ95%. [ 14 C]Palmitoyl-CoA (50 mCi/mmol) was prepared in the same way except that radiolabeled palmitic acid was not diluted with unlabeled material.
Fully processed H-Ras containing an N-terminal polyhistidine tag was produced in Sf9 cells using a recombinant baculovirus vector (obtained as a generous gift from Prof. S. L. Hofmann, University of Texas) and purified on Ni 2ϩ -NTA-agarose (28) with the following modifications. The microsome fraction from 0.5 ϫ 10 9 infected Sf9 cells was suspended in 10 ml of buffer (10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM MgCl 2 , 0.1 mM EDTA, 0.1 mM diethylenetriaminepentaacetic acid, 1 mM dithiothreitol, 10 M GDP, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml leupeptin), and 1.8 ml of 0.4 M octyl glucoside (U. S. Biochemical Corp.) was added. The mixture was rocked at 4°C for 1 h and then centrifuged at 125,000 ϫ g for 1 h at 4°C. To remove the palmitoyl groups from H-Ras, 12 ml of supernatant was mixed with 3.5 ml of a 4 M NH 2 OH solution which was previously adjusted to pH 7.5 with KOH. After incubating overnight at 4°C, the depalmitoylated H-Ras was purified with Ni 2ϩ -NTA-agarose as described (28) . Neutral NH 2 OH does not cleave oxyesters under these conditions. The processed form of H-Ras with both palmitoylation sites (cysteines 181 and 184) mutated to serine was prepared as described (35) . Recombinant protein farnesyltransferase, non-lipidated H-Ras containing an intact Cys-Ali-Ali-Xaa C terminus (produced in Escherichia coli), and in vitro farnesylated bacterial H-Ras were prepared as described (36) .
PPT Assays-Assays were developed that use either N-Ras-16-mer or fully processed and chemically depalmitoylated H-Ras from Sf9 cell membranes. The peptide assay was carried out by incubating 1 pmol of N-Ras-16-mer with rat liver microsomes and 40 M [
14 C]palmitoyl-CoA in a total volume of 50 l containing 10 mM Hepes, pH 7.4, 1 mM dithiothreitol, 1 mM EGTA, 2 mM MgCl 2 , 25 mM octyl glucoside, 20 mM NaCl at 37°C for 1 h. The reaction was quenched with 200 l of methanol, and the mixture was dried in a Speed-Vac concentrator (Savant). The residue was extracted with two 20-l portions of methanol, extracts were combined, and the solution was applied to a reverse phase TLC plate (RP-18, F-254, 20 ϫ 20-cm plate, Merck). The plate was developed in a glass tank with 50% acetonitrile, 50% methanol, 0.03% trifluoroacetic acid until the solvent front was Ϸ1 cm from the top of the plate. After drying the plate for 10 -20 min at room temperature, it was sprayed with EN 3 HANCE (DuPont NEN), wrapped with Saran Wrap, placed in a film cassette against film (Kodak X-AR), and exposed at Ϫ80°C for typically 12-16 h.
Assays with H-Ras protein were carried out by incubating enzyme sample (in the range 8 g (solubilized crude PPT) to Ϸ10 ng (PPT after gel filtration)) with 1.6 M depalmitoylated H-Ras and 20 M [ 3 H]palmitoyl-CoA (5 Ci/mmol) in 25 l of buffer (50 mM Pipes, pH 6.3, 5 mM MgCl 2 , 10 mM NaCl, 1 mM dithiothreitol) for 30 min at 37°C. The reaction was quenched by adding 5 l of 5 ϫ Laemmli SDS gel sample buffer containing 50 mM dithiothreitol, and the sample was boiled for 1 min. The sample was microcentrifuged for 2 min, and the supernatant was applied to a 15% Laemmli gel (60 ϫ 80 ϫ 0.75 mm). Following electrophoresis, the gel was soaked once in 50% methanol (30 min), twice in glacial acetic acid (30 min each), once in a 20% solution of 2,5-diphenyloxazole (Sigma) in glacial acetic acid (30 min), and finally once in water (10 min, to precipitate the scintillant in the gel). The gel was dried under vacuum at 60°C, wrapped with Saran Wrap, and placed in a cassette against film for typically 16 h at Ϫ80°C. To quantify the radioactivity incorporated into H-Ras, the gel was fixed and stained with Coomassie Blue. The H-Ras bands in the gel were excised with a razor blade, and the gel pieces were dissolved in 0.5 ml of 30% H 2 O 2 at 50°C overnight in scintillation vials. Scintillation fluid (Bio-Safe-II) was added, and the samples were submitted to scintillation counting.
Analysis of the Palmitoylated N-Ras-16-mer Product-The R F 0.44 spot from the TLC plate (see peptide assay above and Fig. 1A ) was eluted from the scraped solid phase with methanol, the eluant was brought to dryness (Speed-Vac), the residue was redissolved in methanol, and the supernatant after centrifugation was loaded onto a reverse phase HPLC column (Vydac 218TP1010). The column was developed at flow rate of 1 ml/min with a gradient of 20% acetonitrile, 80% water, 0.06% trifluoroacetic acid to 80% acetonitrile, 20% water, 0.06% trifluoroacetic acid over 50 min, and then to 100% acetonitrile, 0.06% trifluoroacetic acid over 5 min, and holding at this solvent for 65 min. Fractions were analyzed by scintillation counting, and product (retention time 70 min, verified by analyzing some of this material on TLC) was obtained after removal of the solvent (Speed-Vac). Radiolabeled palmitic acid elutes at 62 min. The product residue was treated with 100 l of 0.1 N KOH at room temperature for 20 min to remove the palmitoyl group. Ten l of 1 N HCl was added for neutralization, and solvent was removed in a Speed-Vac. The residue was treated with 30 nmol of [ toylated, and demethylated peptide.
Purification of Rat Liver PPT-All procedures were carried out at 4°C unless otherwise noted. Fifteen male, 150 -200 g, Sprague-Dawley rats were sacrificed in a CO 2 chamber. The livers were immediately removed, perfused, and homogenized, and microsomes were prepared as described (33) except that buffers did not contain protease inhibitors (as noted under "Results," some experiments were carried out with protease inhibitors (33) in buffers for all steps from liver homogenation up to and including DEAE-Sephacel chromatography). The washed microsomes were used immediately in the next step. To the microsome pellets was added a total of 300 ml of PPT solubilization buffer (10 mM Tris-HCl, pH 7.4, 0.25 M sucrose, 1 mM EDTA, 150 mM KCl) and the suspension was stirred for 1 h. The sample was centrifuged at 120,000 ϫ g for 1 h, and the supernatant was concentrated by high pressure ultrafiltration (90-mm P10 membrane, Amicon). The sample was concentrated to a volume of Ϸ50 ml, and then diluted back to 300 ml with 10 mM Tris-HCl, pH 7.4. This process was repeated twice except that the final volume was brought to 100 ml after the final concentration.
The sample was applied by gravity flow to a column (2.5 ϫ 41 cm) of DEAE-Sephacel that was pre-equilibrated with 10 mM Tris-HCl, pH 7.4. The column was washed at 2 ml/min (peristaltic pump) with 100 -150 ml of 10 mM Tris-HCl, pH 7.4, and then developed with a linear gradient of 0 -0.5 M KCl in 10 mM Tris-HCl, pH 7.4 (total volume 560 ml, fraction size 15 ml). The fractions containing PPT were concentrated to 90 ml by ultrafiltration, and the KCl concentration was adjusted to 1 M. The sample was applied by gravity flow to an octylSepharose column (2.5 ϫ 12.5 cm) that was pre-equilibrated with 10 mM Tris-HCl, pH 7.4, 1 M KCl. The column was washed at 1 ml/min (peristaltic pump) with 2 column volumes of equilibration buffer, and then developed with a linear gradient in which the octyl glucoside concentration varied from 0 to 2% and in which the concentration of KCl simultaneously varied from 1 to 0 M in 10 mM Tris-HCl, pH 7.4 (total volume 600 ml, fraction size 15 ml).
The enzyme-containing fractions were combined (120 ml total volume) and concentrated to 1 ml in a CentriPrep-10 (Amicon). The sample was diluted to 10 ml with 10 mM Tris-HCl, pH 7.4, concentrated to 1 ml, diluted again to 10 ml, and finally concentrated to 2.5 ml. A portion of this material (0.5 ml) was applied by gravity flow to a column (0.8 ϫ 2 cm) of SP-Sephadex that was pre-equilibrated with 10 mM Tris-HCl, pH 7.4. PPT eluted during washing by gravity flow with the same buffer. The enzyme starts to elute in the void volume, and 0.5-ml fractions were collected. Enzyme-containing fractions were pooled, octyl glucoside and KCl were added to concentrations of 0.1% and 150 mM, respectively, and 40% of the sample was concentrated to 0.1 ml in a Centricon-10 (Amicon). The sample was applied to an S-300 Sephacryl HR gel filtration column (0.4 ϫ 6.5 cm) that was pre-equilibrated with 10 mM Tris-HCl, pH 7.4, 0.1% octyl glucoside, 150 mM KCl. The column was developed with the same buffer at a flow rate of 12.5 l/min by gravity flow. The column was previously calibrated with molecular weight markers. The final preparation of PPT was stored at 4°C, and under these conditions the enzyme lost activity with a half-time of 2 weeks. Activity is completely lost if the enzyme is stored at Ϫ80°C even if glycerol is added.
For silver staining of the SDS gel (Laemmli) shown in Fig. 4B , the published protocol was used (37) . To eliminate unwanted gel bands, all solutions were filtered through 0.45-m syringe or HPLC solvent filters, all samples and solutions were handled while wearing gloves, Laemmli sample buffer was prepared with freshly opened reagent bottles (and then stored at Ϫ20°C), and the gel plates, spacers, and comb were soaked in aqueous SDS.
RESULTS AND DISCUSSION
Enzymatic Palmitoylation of (N-Ras-16mer)-Based on the previous demonstration of N-Ras palmitoylation in a cell-free preparation made from rat liver (30), a synthetic peptide having the C-terminal 16 residues of human N-Ras and a Cterminal S-farnesyl cysteine methyl ester (N-Ras-16-mer) was first used to detect and characterize a PPT activity present in rat liver microsomes. Incubation of the N-Ras-16-mer peptide with rat liver microsomes together with radiolabeled palmitoylCoA results in the appearance of a new radioactive spot on the TLC plate (R F 0.44, Fig. 1A ). This spot was not seen if either peptide or microsomes were omitted from the reaction mixture (Fig. 1A) or if rat liver cytosol fraction was used instead of microsomes (not shown). This spot was also not seen if the assay was carried out with the peptide in which the cysteine residue of N-Ras-16-mer that is not farnesylated (the putative palmitoyl acceptor) contains an S-t-butylthio group instead of SH (Fig. 1A) . Further evidence that the R F 0.44 spot is palmitoylated N-Ras-16-mer is the following: 1) when this spot was eluted from the TLC plate, de-palmitoylated and demethylated with KOH, and radioacetylated with [
3 H]acetic anhydride, a single peak of radioactivity was seen by HPLC analysis that has the same retention time as authentic N-Ras-16-mer treated in an identical manner (not shown). 2) TLC analysis of KOHtreated R F 0.44 material shows palmitic [
14 C]acid as the only radiolabeled product.
3) The R F 0.44 spot was not seen when the N-Ras peptide containing serine instead of cysteine at the palmitoylation site was used in the assay (not shown).
In light of the fact that prenylated peptides which also contain a non-lipidated cysteine can be non-enzymatically palmitoylated in the presence of synthetic membranes and palmitoylCoA (38) , it was important to examine if palmitoylation of N-Ras-16-mer in the presence of rat liver microsomes is enzyme catalyzed. As shown in Fig. 1A , the R F 0.44 spot was not seen if boiled microsomes were used. The formation of the N-Ras-16-mer-derived R F 0.44 spot was reduced in the presence of peptide substrate analogs. When the peptide containing the S-t-butythio-modified cysteine at the palmitoylation site or the peptide containing the sulfone in place of the thioether of the farnesylated cysteine were included in the assay at a concentration equal to that of N-Ras-16-mer, the formation of the R F 0.44 spot was inhibited by Ϸ50 and Ϸ90%, respectively (not shown). Analysis of the reaction mixture by TLC showed that most of the palmitoyl-CoA was still present. Thus, inhibition by the N-Ras-16-mer analogs is not due to depletion of palmitoylCoA substrate. The results strongly argue for the presence of an enzyme(s) in rat liver microsomes that palmitoylates N-Ras-16-mer which is competitively inhibited by the N-Ras-16-mer analogs. The data is overwhelmingly in support of an enzymatic process for palmitoylation. Interestingly, the non-farnesylated but methylated N-Ras-16-mer did not inhibit the microsome-catalyzed palmitoylation of the farnesylated peptide even when present at a 10-fold higher concentration (not shown).
Despite the initial success with the N-Ras-16-mer peptide, the peptide-based assay proved to be problematic. During the course of the purification of PPT, especially as the crude enzyme preparation aged, an R F Ϸ 0.44 spot was sometimes seen, even when N-Ras-16-mer substrate was omitted from the assay. The identity of this material was not determined. However, as discussed below, purified PPT was found to palmitoylate the N-Ras-16-mer peptide, and the peptide assay was not problematic if purified PPT was used.
Enzymatic Palmitoylation of H-Ras-A second assay for PPT was developed using fully processed H-Ras produced in baculovirus-infected insect cells (28) that was chemically depalmitoylated with a neutral solution of NH 2 OH under conditions which do not lead to C-terminal demethylation ("Experimental Procedures"). As shown in Fig. 1B , submission of the assay mixture to SDS-PAGE followed by fluorography of the gel shows the appearance of a radiolabeled protein band of apparent molecular mass of Ϸ26 kDa. This band migrates at the position of fully lipidated H-Ras that was radio-palmitoylated in Sf9 cells (Fig. 1C) . Careful examination of the fluorograph reveals two closely migrating radiolabeled bands, neither of which was seen if H-Ras was omitted from the assay (Fig. 1B) .
Additional features of this double band phenomenon are presented below. Other bands of radio-palmitoylated proteins migrating much slower than H-Ras in the gel are also seen (Fig.  1B) . Since these are seen in the absence of added H-Ras, and since the intensities of these bands progressively decrease during the course of PPT purification, they are presumably other palmitoylated components in rat liver microsomes. This fact is the reason why it is critical to separate the proteins by SDS-PAGE prior to scintillation counting so that the assay monitors only H-Ras palmitoylation. As also shown in Fig. 1B , in the absence of added microsomes or in the presence of boiled microsomes, a small amount of H-Ras palmitoylation occurs. The enzymatic reaction under the standard assay conditions typically yields 4 -6-fold higher amounts of H-Ras palmitoylation than if enzyme is omitted from the assay mixture, and this ratio increases proportionally if more and more enzyme is added. When the H-Ras mutant containing serine in place of cysteine at positions 181 and 184 was used, no radiolabeled band was seen in the position of the gel where H-Ras migrates (Fig. 1B) . This is in agreement with previous studies of H-Ras palmitoylation in vivo (8) and strongly suggests that palmitoylation of wild type H-Ras occurs at position 181 and/or 184. Treatment of Laemmli gels with a neutral solution of NH 2 OH results in a Ͼ80% loss of the H-Ras-associated cpm, which is consistent with a thioester Ras-palmitoyl linkage (27) . Although the rate of enzymatic palmitoylation of H-Ras is constant in the pH range 6 -7.5, the non-enzymatic rate is 4 -5-fold higher at pH 7.5 than at pH 6.0. This latter result is expected for the non-enzymatic reaction where thiolate and not thiol is almost certainly the reactant, and the data further confirms the enzymatic nature of H-Ras palmitoylation when microsomes are added.
A number of different rat tissues were examined for the presence of PPT in extracts prepared by treating membranes with salt-containing buffer (see below). Both the N-Ras-16-mer and H-Ras assays were used. With brain, the activity was Ϸ10 -20% of that measured with liver, and little if any activity was seen with spleen, heart, lung, or muscle. Thus, rat liver was used for purification of PPT. Purification of PPT using the H-Ras Assay-It was consistently found (seven independent purifications) that most of the PPT activity spun down with the microsome fraction following homogenation of rat liver. Several conditions were explored for solubilizing the enzyme from the membranes, and it was found that Ͼ75% of the PPT was consistently solubilized if the membranes were washed with two portions of buffer containing 150 mM KCl. The fact that PPT activity is found in the soluble extract obtained from salt washed membranes further supports the idea that H-Ras palmitoylation is enzyme catalyzed and is not simply due to the juxtaposition of H-Ras and palmitoyl-CoA in membranes. Comparable yields of PPT could be extracted from membranes using buffer containing 1% octyl glucoside, and this enzyme displayed the same chromatographic properties as salt-extracted PPT. Due to the possible difference in apparent specific activity of membrane-bound and solubilized PPT, it is difficult to compare the amount of PPT activity solubilized to that originally present in the membranes. However, when the microsomes were assay for PPT after two washes with salt-containing buffer, it was found that 20 -40% of the original activity remained; thus much of the PPT was solubilized.
As shown in Fig. 2A , chromatography of crude PPT on DEAE-Sephacel yields a single peak of activity eluting early in the salt gradient. When the fractions were assayed with N-Ras-16-mer, the same profile of PPT elution was seen (not shown), which suggests that a single enzyme might palmitoylate H-Ras protein and N-Ras-16-mer peptide. The sharp elution of PPT from the column suggests that the enzyme has indeed been solubilized into a non-aggregated form; this is also supported by gel filtration described below. As shown in Fig. 1C , DEAESephacel-purified PPT yields only a single band of radiolabeled H-Ras, which is in contrast to the results obtained with microsomes where a double band pattern is seen (Fig. 1B) . As also shown in Fig. 1C , the single radiolabeled H-Ras species obtained with partially purified PPT co-migrates with palmitoylated H-Ras obtained from Sf9 cells that were pulsed with [ 3 H]palmitate as described (28) , which suggests that the product of in vitro palmitoylation is representative of the in vivo process. The reason(s) for the double band pattern seen with microsomes is not known, but it may be due to further alteration of H-Ras (such as demethylation) by one or more enzymes present in microsomes.
In some chromatography runs, a second minor peak of PPT activity eluted from the column at a position in the buffer gradient corresponding to Ϸ0.4 M KCl (not shown). If the time between liver homogenation and DEAE-Sephacel steps was increased, the later-eluting enzyme peak became smaller as the earlier-eluting enzyme peak became larger (not shown). It was thus suspected that this latter peak might be the non-proteolyzed form of PPT. Indeed, when protease inhibitors were included in buffers used for all steps up to and including chromatography on DEAE-Sephacel, all of the PPT activity eluted in the later peak (Fig. 2B ). When this material was left overnight at 4°C; however, a significant amount of protein precipitation occurred, and virtually all of the PPT activity was lost. This also happened when this material was concentrated by ultrafiltration immediately after it eluted from the column. The addition of 2% octyl glucoside to the DEAE-Sephacel fractions did not prevent the lost of activity. Attempts to recover PPT activity by suspending the precipitate in buffer with high salt (1 M KCl) or with 2% octyl glucoside were unsuccessful. Based on these results and the fact that this later eluting PPT coelutes with a major peak of cellular protein (Fig. 2B) , it was decided to proceed with the purification of the putative proteolyzed enzyme, especially since, in seven independent purifications, the non-proteolyzed PPT was not seen in experiments using buffers without protease inhibitors (Fig. 2A) . As indicated in Table I , the combined solubilization and DEAE-Sephacel steps result in a 22-fold increase in the specific activity of PPT. Fig. 3 shows the result of chromatography of PPT on octylSepharose. A single peak of enzymatic activity is seen, and this step results in an additional purification of 19-fold; however, after this step, concentration of the sample by ultrafiltration in preparation for the next column resulted in a significant loss of PPT activity (Table I ). This problem was not prevented if the ultrafiltration membrane was pretreated with BSA or rehydrated dry non-fat milk or if additional octyl glucoside was added prior to concentration. Use of ultrafiltration and membranes devices from Amicon, Pharmacia, or Millipore did not remedy the problem. Since this enzyme binds only very weakly to DEAE-Sephacel (Fig. 1A) or SP-Sephadex (see below), attempts to concentrate the fractions by ion-exchange chromatography were not successful.
The concentrated sample was applied to a SP-Sephadex column, resulting in an additional 34-fold purification for the combined chromatography and subsequent ultrafiltration steps (Table I ). The material was submitted to gel filtration (Fig. 4) . A single peak of PPT activity eluted from the column with an apparent molecular mass of Ϸ60 -70 kDa. When crude PPT from an earlier purification scheme (DEAE-Sephacel followed by SP-Sephadex) was submitted to gel filtration in the same way, the elution position of the enzyme relative to the standards was the same as in Fig. 4 (not shown).
As shown in Fig. 4B , the silver-stained gel of SDS-PAGEanalyzed fractions from the S-300 Sephacryl HR column (Fig.  4A ) reveals two closely migrating major binds whose intensities are well correlated with the enzymatic activity measured for individual fractions (Fig. 4A) . The apparent molecular masses of these bands are Ϸ30 and Ϸ33 kDa. The PPT-containing fractions from this column were pooled, the KCl concentration was increased to 1 M, the sample was applied to a column of octyl-Sepharose (0.9 ϫ 15.7 cm), and the column was developed with the same gradient as described for Fig. 3 (scaled appropriately). A single peak of PPT activity was eluted, and the profile of enzymatic activity again correlated exactly with the intensities of the Ϸ30 and Ϸ33 kDa bands when the column fractions were assayed with H-Ras substrate and submitted to SDS-PAGE (not shown). It is not clear at this point if PPT is a heterodimer composed of Ϸ30 and Ϸ33 kDa subunits or whether these two protein bands represent different proteolysis products of a single polypeptide.
Properties of Purified PPT-Fully purified PPT was used to examine some of its properties. As is the case with crude PPT (Fig. 1B) , no detectable palmitoylation occurred if the H-Ras mutant containing serine in place of cysteine at positions 181 and 184 was used in the standard assay (not shown). The a Protein in microsomes was assayed with the Lowry method, and the Bradford dye-binding assay (Bio-Rad) was used in all subsequent steps. BSA was used as a standard in all cases.
b All assays were done by the SDS-PAGE method using H-Ras substrate. One unit is the amount of PPT that palmitoylates 1 pmol of H-Ras per min using the assay conditions given under "Experimental Procedures."
c PPT activity in microsomes cannot be accurately determined. However, since most of the activity is solubilized, it is assumed that the total microunits of PPT in the solubilized fraction is equal to the total units in the microsomes.
d The ultrafiltration carried out after this chromatographic step resulted in significant loss of protein, and the numbers given are for the combined chromatography and ultrafiltration steps.
e As described under "Experimental Procedures," only a portion of the sample from the previous step was processed in this step. The numbers listed have been scaled to give the yields of material had all of the sample from the previous step been utilized.
f The amount of protein was estimated from the intensity of silver-stained bands in the gel (Fig. 4B ) in comparison to the stain intensities of known amounts of BSA. 
FIG. 4.
A, chromatography of PPT on S-300 Sephacryl HR as described under "Experimental Procedures." Activity was determined with the H-Ras-based assay. The column was calibrated with molecular mass markers: blue dextran, 2,000 kDa; aldolase 158 kDa; BSA, 67 kDa; chymotrypsinogen A, 25 kDa (all from Sigma). B, silver-stained SDS-PAGE of the indicated fractions from the gel filtration column (A). Bars indicate the position of prestained molecular weight markers (Bio-Rad).
strate for PPT-H-Ras that is produced from an E. coli expression system ("Experimental Procedures") is not lipidated and contains a full-length Cys-Ali-Ali-Xaa C-terminal sequence (36) . The bacterial H-Ras shows stoichiometric binding of GTP (36) , which suggests that it has a native structure. Using the standard H-Ras assay, bacterially expressed H-Ras was not detectably palmitoylated by crude or purified PPT when it was present in the assay instead of farnesylated H-Ras purified from insect cells (not shown). This was true even when a 5-fold higher concentration of bacterial H-Ras (8 M) was used. Bacterial H-Ras that was stoichiometrically farnesylated in vitro with purified recombinant protein farnesyltransferase (36) was also not detectably palmitoylated by PPT when tested using the standard assay conditions. These results along with those mentioned above for the N-Ras peptide suggest, but do not prove, that farnesylation and possibly C-terminal methylation of HRas are a prerequisite for its palmitoylation. It may be noted that in vitro farnesylation of bacterial H-Ras is sufficient to restore its ability to activate mitogen-activated protein kinase in a cell-free system (36) , which suggests that this bacterial protein is functional in some assays. To fully explore the substrate requirements of PPT it will be necessary to analyze the palmitoylation pattern of a series of synthetic Ras peptides that contain progressive C-terminal modifications since all of the differentially processed forms of H-Ras are not readily available. The fact that non-farnesylated H-Ras is not a substrate for PPT is consistent with previous transfection studies showing that palmitoylation of Ras proteins is not seen in vivo if farnesylation is prevented by mutation of cysteine 186 to serine (8) . Finally, it was found that C terminally processed H-Ras loaded with GTP or GDP (39) were equivalent substrates for purified PPT (not shown).
Concluding Remarks-There is a lively debate about whether protein palmitoylation in cells is enzyme catalyzed or occurs by a non-enzymatic second-order reaction between thiolate and palmitoyl-CoA. The work reported in this study clearly demonstrates the presence in rat liver of an enzyme capable of palmitoylating Ras proteins. On the other hand, the palmitoylation of P o glycoprotein in myelin may be a non-enzymatic process (43) . The fact the PPT is solubilized by 150 mM KCl suggests that it may not be tightly bound to membranes; however, the membrane topology of the putative full-length PPT remains to be established. With purified PPT in hand, it should be possible to obtain the putative full-length enzyme by expression of its cDNA. It has been previously shown that Ras proteins cannot be palmitoylated unless they are farnesylated (8) . The results of this study suggest that farnesylation and possibly C-terminal methylation of H-Ras are prerequisites for palmitoylation by purified PPT.
Since PPT is the first protein palmitoyltransferase to be purified to apparent homogeneity, it is somewhat premature to compare the properties of PPT to other protein palmitoyltransferases that have been detected in cell homogenates. Berthiaume and Resh (40) recently detected a palmitoyltransferase that transfers the palmitoyl group to src-related protein kinases that are N terminally myristoylated (40) . It appears from Fig. 6 of their study that, compared to 10 M palmitoyl-CoA, 10 M myristoyl-CoA produces somewhat less inhibition of radiopalmitoylation of their protein acceptor. This indicates that the enzyme(s) in their extract, compared to PPT, is much less selective for palmitoylation versus myristoylation, which in turn suggests that PPT is distinct from the enzyme(s) present in the extract reported by Berthiaume and Resh (40) . Schmidt and co-workers (41) have been studying the palmitoylation of viral glycoproteins in a cell-free homogenate. The enzyme(s) involved is probably distinct from PPT because detergents, but not high salt, are able to solubilize it from membranes (42) .
Further work will be required to establish whether PPT is the enzyme responsible for Ras palmitoylation in vivo, and whether this enzyme undergoes regulation in cells. Very little is known about the function of Ras palmitoylation in cells, and the purification of PPT is a necessary early step in our understanding of this post-translational event.
